- Home
- TNYA vs MGX Comparison
TNYA vs MGX Comparison
Compare TNYA & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- MGX
- Stock Information
- Founded
- TNYA 2016
- MGX 2018
- Country
- TNYA United States
- MGX United States
- Employees
- TNYA N/A
- MGX N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- MGX
- Sector
- TNYA Health Care
- MGX
- Exchange
- TNYA Nasdaq
- MGX NYSE
- Market Cap
- TNYA 73.8M
- MGX 62.1M
- IPO Year
- TNYA 2021
- MGX 2024
- Fundamental
- Price
- TNYA $0.69
- MGX $2.17
- Analyst Decision
- TNYA Strong Buy
- MGX Strong Buy
- Analyst Count
- TNYA 5
- MGX 4
- Target Price
- TNYA $8.60
- MGX $13.00
- AVG Volume (30 Days)
- TNYA 2.3M
- MGX 912.4K
- Earning Date
- TNYA 08-07-2025
- MGX 08-13-2025
- Dividend Yield
- TNYA N/A
- MGX N/A
- EPS Growth
- TNYA N/A
- MGX N/A
- EPS
- TNYA N/A
- MGX N/A
- Revenue
- TNYA N/A
- MGX $45,263,000.00
- Revenue This Year
- TNYA N/A
- MGX N/A
- Revenue Next Year
- TNYA N/A
- MGX $11.75
- P/E Ratio
- TNYA N/A
- MGX N/A
- Revenue Growth
- TNYA N/A
- MGX N/A
- 52 Week Low
- TNYA $0.36
- MGX $1.23
- 52 Week High
- TNYA $4.06
- MGX $5.50
- Technical
- Relative Strength Index (RSI)
- TNYA 62.18
- MGX 71.83
- Support Level
- TNYA $0.58
- MGX $1.45
- Resistance Level
- TNYA $0.70
- MGX $2.47
- Average True Range (ATR)
- TNYA 0.05
- MGX 0.16
- MACD
- TNYA 0.00
- MGX 0.09
- Stochastic Oscillator
- TNYA 93.66
- MGX 75.47
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.